Imidazoline
| Imidazoline | |
|---|---|
| |
| IUPAC name | 4,5-dihydro-1H-imidazole |
| Identifiers | |
| CAS number | |
| SMILES | C=1NCCN=1 |
| Properties | |
| Molecular formula | C3H6N2 |
| Molar mass | 70.093 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references | |
|
WikiDoc Resources for Imidazoline | |
|
Articles | |
|---|---|
|
Most recent articles on Imidazoline Most cited articles on Imidazoline | |
|
Media | |
|
Powerpoint slides on Imidazoline | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Imidazoline at Clinical Trials.gov Clinical Trials on Imidazoline at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Imidazoline
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Imidazoline Discussion groups on Imidazoline Patient Handouts on Imidazoline Directions to Hospitals Treating Imidazoline Risk calculators and risk factors for Imidazoline
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Imidazoline | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Overview
Imidazoline is a nitrogen-containing heterocycle derived from imidazole. The ring contains an imine bond, and the carbons at the 4 and 5 positions are singly bonded, rather than doubly bonded for the case of imidazole. Imidazolines are structurally related to guanidines and amidines.
Like imidazole, imidazoline-based compounds have been used as N-heterocyclic carbene ligands on various transition metals. It is found in the commercially available second generation Grubbs' catalyst.
Biological role
Many imidazolines are biologically active.[1] Most bio-active derivatives bear a substituent (aryl or alkyl group) on the carbon between the nitrogen centers. Some brand names include oxymetazoline, xylometazoline, tetrahydrozoline, and naphazoline.
References
- ↑ N. MacInnes and S. Duty (2004). "Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway". Br J Pharmacol 143 (8): 952-959. doi:10.1038/sj.bjp.0706019.
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies

